

• **Name:**

Masanori Terashima

• **Current Position:**

Chief, Division of Gastric Surgery, Shizuoka Cancer Center

• **Country:**

Japan

• **Educational Background:**

1983 M.D., cum laude, Iwate Medical University

1987 Ph.D. (Dr. of Medical Science), Iwate Medical University
(Thesis: Analysis of the Chemosensitivity Test by Human
Tumor Clonogenic Assay and Subrenal Capsule Assay)

• **Professional Experience:**

- 1984-1985 Research Fellow, Department of Clinical Oncology,
Cancer Institute Hospital, Tokyo
- 1987-1994 Member of Medical Staff, Department of Surgery 1,
Iwate Medical University
- 1994-1995 Research Fellow in Medicine, Division of Cancer Pharmacology
Dana-Farber Cancer Institute, MA
- 1994-2002 Assistant Professor, Department of Surgery 1,
Iwate Medical University
- 2002-2008 Associate Professor, Department of Surgery 1,
Fukushima Medical University
- 2008- Chief, Division of Gastric Surgery
Shizuoka Cancer Center
- 2006- Visiting Professor
Iwate Medical University
- 2008- Visiting Assistant Professor
Fukushima Medical University

• **Professional Organizations:**

- 2012- Board of Director
Japanese Gastric Cancer Association
- 2016- Chairman
Stomach Cancer Study Group, Japan Clinical Oncology Group

• **Main Scientific Publications:**

Terashima M, Iwasaki Y, Mizusawa J, Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito Y, Kaji M, Kimura Y, Hirao M, Yamada M, Kurita A, Takagi M, Boku N, Sano T, Sasako M; Stomach Cancer Study Group, Japan Clinical Oncology Group. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). *Gastric Cancer*. 2019 Mar 2. doi: 10.1007/s10120-019-00941-z. [Epub ahead of print]

Katai H, Mizusawa J, Katayama H, Kunisaki C, Sakuramoto S, Inaki N, Kinoshita T, Iwasaki Y, Misawa K, Takiguchi N, Kaji M, Okitsu H, Yoshikawa T, Terashima M; Stomach Cancer Study Group of Japan Clinical Oncology Group. Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401. *Gastric Cancer*. 2019 Feb 20. doi: 10.1007/s10120-019-00929-9. [Epub ahead of print]

Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Fukushima N, Hato S, Choda Y, Yabusaki H, Yoshida K, Ito S, Takeno A, Yasuda T, Kawachi Y, Katayama H, Fukuda H, Boku N, Sano T, Sasako M. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. *Lancet Gastroenterol Hepatol*. 2019 Mar;4(3):208-216. doi: 10.1016/S2468-1253(18)30383-2.

Kurokawa Y, Doki Y, Mizusawa J, Terashima M, Katai H, Yoshikawa T, Kimura Y, Takiguchi S, Nishida Y, Fukushima N, Iwasaki Y, Kaji M, Hirao M, Katayama H, Sasako M. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. *Lancet Gastroenterol Hepatol*. 3(7): 460-468, 2018.

Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M, for the ACTS-GC Group. TOP2A, GGH, and PECAM1 are associated with hematogenous, lymph node, and peritoneal recurrence in stage II/III gastric cancer patients enrolled in the ACTS-GC study. *Oncotarget*, 8(34): 57574-57582, 2017